Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

Inflammatory Bowel Disease

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Inflamm Bowel Dis.

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP

doi: 10.1093/ibd/izz192.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis

United European Gastroenterol J

Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S

doi: 10.1177/2050640620972602

Inflammatory Bowel Disease

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

Clin Gastroenterol Hepatol.

Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L

doi: 10.1016/j.cgh.2020.04.071.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

Inflamm Bowel Dis.

Martin Arranz E, Suarez Ferrer C, García Ramírez L, Rueda García JL, Sánchez-Azofra M, Poza Cordón J, Noci J, Zabana Y, Barreiro-de Acosta M, Martín-Arranz MD

doi: 10.1093/ibd/izaa142.

Inflammatory Bowel Disease

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease

Inflamm Bowel Dis.

Barnes EL, Long MD, Kappelman MD, Martin CF, Sandler RS

doi: 10.1093/ibd/izy378.

Inflammatory Bowel Disease

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission

J Gastroenterol Hepatol.

Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A

doi: 10.1111/jgh.14751.

Inflammatory Bowel Disease

The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Inflamm Bowel Dis.

Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V

doi: 10.1093/ibd/izaa122.

Related content

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission

The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis